Alignment Healthcare

ALHC · NYSE · Healthcare · United States

Financials at a glance

Source: SEC XBRL

Annual

FY2023FY2024FY2025$1.8B$1.8B$2.7B$2.7B$3.9B$3.9B-0.0% margin-0.0% marginRevenueNet margin

Quarterly · last 8

Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26$628.6M$628.6M$681.3M$681.3M$692.4M$692.4M$926.9M$926.9M$1.0B$1.0B$993.7M$993.7M$1.2B$1.2B$1.3B$1.3B2.7% margin2.7% marginRevenueNet margin

Revenue (FY2025)

$3.9B

Net margin

-0.0%

ROE

-0.4%

Revenue CAGR (2y)

+48.1%

EPS (FY2025)

0.00

Net profit (FY2025)

$-724,000

Ask MarketChacha about ALHC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

  • Aug 4, 2026

    ALHC fell on Raymond James downgrading the stock to Outperform from Strong Buy (PT cut to $19) citing reduced earnings visibility from expansion outside California and ongoing spending on growth initiatives; additional pressure came from a law firm investigation into potential securities law violations tied to accounting questions.

  • Jul 27, 2026

    ALHC fell amid continued investor reaction to whistleblower allegations of accounting irregularities and financial misstatements, with multiple law firms (including Kaplan Fox) issuing new investor alerts and launching investigations into potential securities violations.

    source 1source 2· confidence: medium
  • Jul 23, 2026

    ALHC fell on news of Hagens Berman launching an investigation into potential securities law violations following whistleblower allegations of financial manipulation and accounting misconduct.

    source 1· confidence: high
  • Jul 22, 2026

    Alignment Healthcare shares fell on news of a Kaplan Fox investigation into potential securities law violations stemming from whistleblower claims of accounting misconduct and financial overstatement.

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

PeriodRevenueNet profitEPSNet marginROE
FY2025$3.9B$-724,0000.00-0.0%-0.4%
FY2024$2.7B$-128.0M-0.67-4.7%-128.2%
FY2023$1.8B$-148.0M-0.79-8.2%-94.3%

Quarterly

PeriodRevenueNet profitEPSNet margin
2026Q2$1.3B$36.6M0.172.7%
2026Q1$1.2B$11.4M0.050.9%
2025Q3$993.7M$3.7M0.020.4%
2025Q2$1.0B$15.7M0.071.5%
2025Q1$926.9M$-9.1M-0.05-1.0%
2024Q3$692.4M$-26.4M-0.14-3.8%
2024Q2$681.3M$-24.0M-0.13-3.5%
2024Q1$628.6M$-46.5M-0.25-7.4%
2023Q3$450.2M$-35.0M-0.19-7.8%
2023Q2$456.9M$-28.5M-0.15-6.2%
2023Q1$434.8M$-37.3M-0.20-8.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.